- Reagents
- Kits
- Instruments
- Chemiluminescence
- Immunofluorescence
- ELISA
- Immunochromatography
Congestive Heart Disease Marker Tests Market size was valued at USD 9.2 billion in 2022 poised to grow at a CAGR of 9% during the forecast period 2023 to 2029. Congestive heart disease marker tests are diagnostic tests to measure the concentration of the protein to identify the occurrence and disease phase. The cardiac diseases can be prevented by identifying the heart conditions by cardiac biomarker testing is helpful for the immediate diagnosis and treatment. Cardiac biomarkers evaluate the cardiac function and help in identifying the severity and complexity of procedures to treat CVD. The primary indications for the CVD are acute coronary syndrome (ACS) that include congestive heart failure (CHF), angina pectoris (AP) peripheral artery disease (PAD), acute myocardial infarction (AMI) and others. The causes for CVD are include smoking, high blood pressure, diabetes, inadequate exercise, stress, unhealthy diet, obesity, high blood cholesterol, and alcoholism. The most commonly used cardiac biomarkers for diagnosis of CVD include troponin I and T, CK-MB, BNPs, myoglobin, and IMA, among others. Launch of new products, technological advancements, acquisitions and mergers, and collaborations are some key strategies followed by various industry players to increase their share in the congestive heart disease marker test market.
Congestive Heart Disease Marker Tests Market Key Developments:
- For instance, in July 2011, Thermo Fisher Scientific it inked a license agreement with Alere Inc. to develop its novel Thermo Scientific B.R.A.H.M.S. biomarker assays on leading point-of-care Triage platform.
Global Congestive Heart Disease Marker Tests Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
9%
Largest Market
North-America
Fastest Growing Market
Europe
Congestive Heart Disease Marker Tests Market Dynamics
Increase in geriatric population, rise in funding from private-public organizations for cardiac biomarkers research, and ongoing research and clinical trials for identification of the newer cardiac biomarkers are the key factors boost the global market over the forecast period. Moreover, promising features such as high accuracy, quick outcomes and economic pricing of cardiac point of care (POC) testing, and increase in the adoption of new diagnostic tools by healthcare professionals and cost affordability for patients might propel the global market over the forecast period. However, factors technical problems such as sample collection and storage, stringent regulatory guidelines, lack of reimbursement systems hamper the growth of market over the forecast period.
North America got significant share
Congestive Heart Disease Marker Tests Market Regional Analysis
Geographically, global market has been segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds the dominant share owing to increase in the prevalence of congestive heart failures (According to the American Heart Association (AHA), nearly five Mn individuals experience heart failure and about 550,000 new cases are diagnosed each year in the United States). Rising aging population, increase in inclination toward point-of-care testing, and elevated frequency of cardiovascular disorders are the key factors expected to drive the market over the forecast period. Europe holds a major share in global market attributed to increase in the prevalence of congestive heart failure (According to British Heart Foundation (BHF) approximately 7 Mn people are suffering from the various cardiovascular disease in U.K.). Rise in incidence of congestive heart disease in U.K. (approximately 4000 cases per year in new born babies), increase in the research and development, and novel innovations in congestive heart disease biomarker tests might fuel the growth of the market. The Asia-Pacific is expected to exhibit significant growth over forecast period owing to increase in prevalence of Myocardial Infarction, public and private initiatives to increase the awareness related to early cardiac disease diagnosis in physicians and patients.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Global Congestive Heart Disease Marker Tests Market Segmentation
By Product Type
By Test Type
- Myocardial muscle Creatine Kinase (CK-MB)
- Myoglobin
- Troponins (T and I)
- Ischemia Modified Albumin (IMA)
- NT-proBNP or Brain Natriuretic Peptide (BNP) or
- Others
By Application
- Myocardial Infarction
- Acute Coronary Syndrome
- Congestive Heart Failure
- Atherosclerosis
- Others
By End User
- Hospitals
- Clinics
- Diagnostic Centres
- Others
Frequently Asked Questions
The congestive heart disease marker tests market size was valued at USD 9.2 billion in 2022
The key segments covered in the congestive heart disease marker tests market are: by product type, test type, application, and end-users
The congestive heart disease marker tests market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
Table of Contents
| 1. Research Methodology |
| 1.1. Secondary and Primary research |
| 1.1.1. Secondary Sources |
| 1.1.2. Primary Sources |
| 1.2. Market Revenue Estimation Methodology |
| 1.3. Key Assumptions |
| 1.4. Acronyms |
| 2. Scope of Study |
| 2.1. Market Definition |
| 2.2. Objective of the Research |
| 2.3. Regions covered in the study |
| 3. Executive summary |
| 4. Global Congestive Heart Disease Marker Tests Market Dynamics |
| 4.1. Drivers |
| 4.1.1. Economic Drivers |
| 4.1.2. Demand Side Drivers |
| 4.1.3. Supply Side Drivers |
| 4.2. Restraints |
| 4.3. Opportunities/Unmet Needs of the Market |
| 4.4. Trends |
| 5. Unique Features of the Report |
| 5.1. Competition analysis |
| 5.2. Novel Biomarker Tests 5.3. Epidemiology |
| 6. Global Congestive Heart Disease Marker Tests Market Analysis, By Test Type, 2018 - 2022 and Forecast, 2023 - 2029 |
| 6.1. Myocardial muscle Creatine Kinase (CK-MB) |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 6.2. hs-CRP |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 6.3. Troponins (T and I) |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 6.4. Ischemia Modified Albumin (IMA) |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 6.5. NT-proBNP or Brain Natriuretic Peptide (BNP) |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 6.6. Myoglobin |
| 6.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 6.7. Others |
| 6.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 7. Global Congestive Heart Disease Marker Tests Market Forecast, By Application Analysis, 2018 - 2022 and Forecast, 2017 - "2023 |
| 7.1. Myocardial Infarction |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 7.2. Acute Coronary Syndrome |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 7.3. Congestive Heart Failure |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 7.4. Atherosclerosis |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 7.5. Others |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 8. Global Congestive Heart Disease Marker Tests Market Forecast, By End User Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 8.1. Hospitals |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 8.2. Clinics |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 8.3. Diagnostic Centers |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 8.4. Others |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 9. Congestive Heart Disease Marker Tests Market Analysis, By Region, 2018 - 2022 and Forecast, 2023 - 2029 |
| 9.1. North America Congestive Heart Disease Marker Tests Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 9.1.1. Test Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.1.1.1. Myocardial muscle Creatine Kinase (CK-MB) |
| 9.1.1.2. hs-CRP |
| 9.1.1.3. Troponins (T and I) |
| 9.1.1.4. Ischemia Modified Albumin (IMA) |
| 9.1.1.5. NT-proBNP or Brain Natriuretic Peptide (BNP) |
| 9.1.1.6. Myoglobin |
| 9.1.1.7. Others |
| 9.1.2. Application Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.1.2.1. Myocardial Infarction |
| 9.1.2.2. Acute Coronary Syndrome |
| 9.1.2.3. Congestive Heart Failure |
| 9.1.3.4. Atherosclerosis |
| 9.1.3.5. Others |
| 9.1.3. End User Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.1.3.1. Hospitals |
| 9.1.3.2. Clinics |
| 9.1.3.3. Diagnostic Centers |
| 9.1.3.4. Others |
| 9.1.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.1.4.1. US |
| 9.1.4.2. Canada |
| 9.2. Europe Congestive Heart Disease Marker Tests Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 9.2.1. Test Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.2.1.1. Myocardial muscle Creatine Kinase (CK-MB) |
| 9.2.1.2. hs-CRP |
| 9.2.1.3. Troponins (T and I) |
| 9.2.1.4. Ischemia Modified Albumin (IMA) |
| 9.2.1.5. NT-proBNP or Brain Natriuretic Peptide (BNP) |
| 9.2.1.6. Myoglobin |
| 9.2.1.7. Others |
| 9.2.2. Application Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.2.2.1. Myocardial Infarction |
| 9.2.2.2. Acute Coronary Syndrome |
| 9.2.2.3. Congestive Heart Failure |
| 9.2.2.4. Atherosclerosis |
| 9.2.2.5. Others |
| 9.2.3. End User Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.2.3.1. Hospitals |
| 9.2.3.2. Clinics |
| 9.2.3.3. Diagnostic Centers |
| 9.2.3.4. Others |
| 9.2.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.2.4.1. UK |
| 9.2.4.2. Germany |
| 9.2.4.3. France |
| 9.2.4.4. Italy |
| 9.2.4.5. Spain |
| 9.2.4.6. Russia |
| 9.2.4.7. Poland |
| 9.2.4.8. Rest of Europe |
| 9.3. Asia-Pacific Congestive Heart Disease Marker Tests Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 9.3.1. Test Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.3.1.1. Myocardial muscle Creatine Kinase (CK-MB) |
| 9.3.1.2. hs-CRP |
| 9.3.1.3. Troponins (T and I) |
| 9.3.1.4. Ischemia Modified Albumin (IMA) |
| 9.3.1.5. NT-proBNP or Brain Natriuretic Peptide (BNP) |
| 9.3.1.6. Myoglobin |
| 9.3.1.7. Others |
| 9.3.2. Application Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.3.2.1. Myocardial Infarction |
| 9.3.2.2. Acute Coronary Syndrome |
| 9.3.2.3. Congestive Heart Failure |
| 9.3.2.4. Atherosclerosis |
| 9.3.2.5. Others |
| 9.3.3. End User Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.3.3.1. Hospitals |
| 9.3.3.2. Clinics |
| 9.3.3.3. Diagnostic Centers |
| 9.3.3.4. Others |
| 9.3.4. Country Analysis (3013 - 3016) and Forecast (3017 - 3033) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.3.4.1. Japan |
| 9.3.4.2. China |
| 9.3.4.3. India |
| 9.3.4.4. ASEAN |
| 9.3.4.5. Australia & New Zealand |
| 9.3.4.6. Rest of Asia-Pacific |
| 9.4. Latin America Congestive Heart Disease Marker Tests Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 9.4.1. Test Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.4.1.1. Myocardial muscle Creatine Kinase (CK-MB) |
| 9.4.1.2. hs-CRP |
| 9.4.1.3. Troponins (T and I) |
| 9.4.1.4. Ischemia Modified Albumin (IMA) |
| 9.4.1.5. NT-proBNP or Brain Natriuretic Peptide (BNP) |
| 9.4.1.6. Myoglobin |
| 9.4.1.7. Others |
| 9.4.2. Application Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.4.2.1. Myocardial Infarction |
| 9.4.2.2. Acute Coronary Syndrome |
| 9.4.2.3. Congestive Heart Failure |
| 9.4.2.4. Atherosclerosis |
| 9.4.2.5. Others |
| 9.4.3. End User Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.4.3.1. Hospitals |
| 9.4.3.2. Clinics |
| 9.4.3.4. Diagnostic Centers |
| 9.4.3.5. Others |
| 9.4.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.4.4.1. Brazil |
| 9.4.4.2. Mexico |
| 9.4.4.3. Argentina |
| 9.4.4.4. Venezuela |
| 9.4.4.5. Rest of Latin America |
| 9.5. Middle East & Africa Congestive Heart Disease Marker Tests Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 9.5.1. Test Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.5.1.1. Myocardial muscle Creatine Kinase (CK-MB) |
| 9.5.1.2. hs-CRP |
| 9.5.1.3. Troponins (T and I) |
| 9.5.1.4. Ischemia Modified Albumin (IMA) |
| 9.5.1.5. NT-proBNP or Brain Natriuretic Peptide (BNP) |
| 9.5.1.6. Myoglobin |
| 9.5.1.7. Others |
| 9.5.2. Application Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.5.2.1. Myocardial Infarction |
| 9.5.2.2. Acute Coronary Syndrome |
| 9.5.2.3. Congestive Heart Failure |
| 9.5.2.4. Atherosclerosis |
| 9.5.2.5. Others |
| 9.5.3. End User Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) and Y-o-Y Growth (%) |
| 9.5.3.1. Hospitals |
| 9.5.3.2. Clinics |
| 9.5.3.3. Diagnostic Centers |